 |
 Video: What is a Stock Split?
|
|
|
| 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH. According to our 89bio stock split history records, 89bio has had 0 splits. | |
|
89bio (ETNB) has 0 splits in our 89bio stock split history database.
Looking at the 89bio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into 89bio shares, starting with a $10,000 purchase of ETNB, presented on a split-history-adjusted basis factoring in the complete 89bio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/12/2019 |
|
| End date: |
04/18/2024 |
|
| Start price/share: |
$19.75 |
|
| End price/share: |
$8.88 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-55.04% |
|
| Average Annual Total Return: |
-16.50% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$4,496.20 |
|
| Years: |
4.43 |
|
|
|
|
|
